Why Amylyx Pharmaceuticals Stock Is On Investors’ Radar

Amylyx Pharmaceuticals (AMLX) has drawn fresh attention after recent trading saw the stock down about 4% on the day, extending declines of roughly 10% over the past week and 22% over the past month.

For investors tracking biotech volatility, this short term pullback sits against a longer backdrop where Amylyx Pharmaceuticals shows a year to date gain of about 16% and a 1 year total return near 174%, paired with a 3 year total return decline of about 50%.

The recent 1 day share price decline of about 4% and 1 month share price fall of around 22% contrast with a positive year to date share price return of roughly 16% and a very strong 1 year total shareholder return near 174%. This suggests momentum has cooled in the short term while longer term holders still sit on sizeable gains.

If this kind of sharp sentiment shift in biotech has your attention, it can be a good moment to scan other healthcare AI opportunities using the 32 healthcare AI stocks.

With Amylyx trading around $13.29, showing an intrinsic discount of about 72% and a discount to the average analyst price target of roughly 76%, the key question is whether this signals a buying opportunity or whether the market is already pricing in future growth.

Most Popular Narrative: 40.2% Undervalued

Against the last close at $13.29, the most followed narrative points to a fair value of $22.20, framing Amylyx as materially discounted on future potential.

The company is targeting post bariatric hypoglycemia, a condition with no FDA approved therapies and an estimated 160,000 patients in the U.S., which creates room for a first approved product like avexitide to establish a new revenue line if pricing and access are secured.

Curious what sits behind that valuation gap? The narrative leans on rapid revenue build out, a meaningful margin shift and a premium earnings multiple that is usually reserved for market favorites.

Result: Fair Value of $22.20 (UNDERVALUED)

However, this story could change quickly if the pivotal LUCIDITY trial for avexitide disappoints or if Amylyx needs fresh capital that dilutes existing shareholders.

Another Angle On Amylyx’s Valuation

Amylyx trades at a P/B of 5.4x, compared with 3.3x for peers and 2.3x for the broader US Pharmaceuticals industry. This represents a steep premium for a company with no revenue today. How comfortable are you paying this valuation when expectations already look demanding?

Next Steps

Given the mix of strong past returns and a demanding valuation, it is worth checking the underlying data for yourself and deciding where you land on the risk and reward balance, starting with the 2 key rewards and 4 important warning signs.

Looking for more investment ideas?

Do not stop with one stock when you can quickly scan fresh ideas that fit different goals, risk levels and income needs using the Simply Wall Street Screener.

• Target potential mispricing by reviewing companies trading on appealing valuations with the 50 high quality undervalued stocks.
• Build a sturdier core for your portfolio by checking companies with healthy finances through the solid balance sheet and fundamentals stocks screener (45 results).
• Spot early opportunities before they hit the spotlight by searching through a screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.